| Literature DB >> 35807898 |
Takayuki Yamaji1, Takahiro Harada1, Yu Hashimoto1, Yukiko Nakano1, Masato Kajikawa2, Kenichi Yoshimura2,3, Chikara Goto4, Aya Mizobuchi5, Shunsuke Tanigawa5, Farina Mohamad Yusoff5, Shinji Kishimoto5, Tatsuya Maruhashi5, Ayumu Nakashima6, Yukihito Higashi2,5.
Abstract
We evaluated the relationship of daily coffee intake with endothelial function assessed by flow-mediated vasodilation and vascular smooth muscle function assessed by nitroglycerine-induced vasodilation in patients with hypertension. A total of 462 patients with hypertension were enrolled in this cross-sectional study. First, we divided the subjects into two groups based on information on daily coffee intake: no coffee group and coffee group. The median coffee intake was two cups per day in the coffee group. There were significant differences in both flow-mediated vasodilation (2.6 ± 2.8% in the no coffee group vs. 3.3 ± 2.9% in the coffee group, p = 0.04) and nitroglycerine-induced vasodilation (9.6 ± 5.5% in the no coffee group vs. 11.3 ± 5.4% in the coffee group, p = 0.02) between the two groups. After adjustment for confounding factors, the odds ratio for endothelial dysfunction (OR: 0.55, 95% CI: 0.32-0.95) and the odds ratio for vascular smooth muscle dysfunction (OR: 0.50, 95% CI: 0.28-0.89) were significantly lower in the coffee group than in the no coffee group. Next, we assessed the relationship of the amount of daily coffee intake with vascular function. Cubic spline curves revealed that patients with hypertension who drank half a cup to 2.5 cups of coffee per day had lower odds ratios for endothelial dysfunction assessed by flow-mediated vasodilation and vascular smooth muscle dysfunction assessed by nitroglycerine-induced vasodilation. Appropriate daily coffee intake might have beneficial effects on endothelial function and vascular smooth muscle function in patients with hypertension.Entities:
Keywords: coffee; endothelial function; flow-mediated vasodilation; nitroglycerine-induced vasodilation
Mesh:
Substances:
Year: 2022 PMID: 35807898 PMCID: PMC9268420 DOI: 10.3390/nu14132719
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Clinical Characteristics of Subjects in Groups According to Daily Coffee Intake.
| Variables | Total | No Coffee | Coffee | |
|---|---|---|---|---|
| Age, year | 65 ± 13 | 67 ± 13 | 64 ± 13 | 0.08 |
| Men, n (%) | 274 (59.7) | 51 (71.8) | 223 (57.5) | 0.02 |
| Body mass index, kg/m2 | 24.4 ± 3.8 | 24.5 ± 3.8 | 24.4 ± 3.7 | 0.84 |
| Heart rate, bpm | 69 ± 11 | 70 ± 14 | 69 ± 11 | 0.49 |
| Systolic blood pressure, mmHg | 130 ± 17 | 133 ± 20 | 129 ± 16 | 0.10 |
| Diastolic blood pressure, mmHg | 79 ± 12 | 81 ± 12 | 78 ± 12 | 0.10 |
| Total cholesterol, mmol/L | 4.91 ± 0.93 | 4.73 ± 0.88 | 4.94 ± 0.93 | 0.12 |
| Triglycerides, mmol/L | 1.28 (0.93, 1.81) | 1.31 (0.86, 1.87) | 1.26 (0.94, 1.80) | 0.63 |
| High-density lipoprotein cholesterol, mmol/L | 1.55 ± 0.41 | 1.55 ± 0.39 | 1.55 ± 0.44 | 0.97 |
| Low-density lipoprotein cholesterol, mmol/L | 2.79 ± 0.78 | 2.61 ± 0.75 | 2.84 ± 0.78 | 0.04 |
| Creatinine, mmol/L | 71.6 (61.0, 85.8) | 84.9 (64.5, 97.2) | 70.7 (60.1, 84.6) | <0.01 |
| Glucose, mmol/L | 5.94 ± 1.28 | 5.88 ± 1.33 | 5.94 ± 1.28 | 0.73 |
| Hemoglobin A1c, % | 5.9 ± 0.9 | 5.8 ± 1.3 | 5.9 ± 0.8 | 0.59 |
| Medical history, n (%) | ||||
| Dyslipidemia | 301 (65.2) | 48 (67.6) | 253 (64.7) | 0.64 |
| Diabetes mellitus | 135 (29.2) | 14 (19.7) | 121 (31.0) | 0.048 |
| Cardiovascular disease, n (%) | 94 (20.6) | 23 (32.4) | 71 (18.4) | <0.01 |
| Smoker, n (%) | 252 (54.7) | 39 (54.9) | 213 (54.6) | 0.96 |
| Medication, n (%) | ||||
| Antihypertensive drugs | 421 (91.9) | 65 (92.9) | 356 (91.8) | 0.75 |
| Lipid-lowering drugs | 190 (62.5) | 30 (62.5) | 160 (62.5) | 1.00 |
| Anti-diabetic drugs | 130 (28.1) | 14 (19.7) | 116 (29.7) | 0.09 |
Figure 1Bar graphs show flow-mediated vasodilation (A) and nitroglycerine-induced vasodilation (B) in patients with hypertension who did not drink coffee and patients with hypertension who drank coffee.
Multivariate Analysis of Endothelial Dysfunction in No Coffee and Coffee Groups.
| Odds Ratio (95% Confidence Interval); | |||||
|---|---|---|---|---|---|
| Coffee | Unadjusted | Model 1 | Model 2 | Model 3 | Model 4 |
| No coffee | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| Coffee | 0.57 (0.34–0.95); 0.03 | 0.58 (0.34–0.99); 0.04 | 0.56 (0.33–0.96); 0.04 | 0.55 (0.32–0.95); 0.03 | 0.55 (0.32–0.95); 0.03 |
Model 1: adjusted for age, sex, and body mass index. Model 2: adjusted for age, sex, body mass index, dyslipidemia, diabetes mellitus, and smokers. Model 3: adjusted for age, sex, body mass index, dyslipidemia, diabetes mellitus, smoker, cardiovascular disease. Model 4; adjusted for age, sex, body mass index, dyslipidemia, diabetes mellitus, smokers, cardiovascular disease, and systolic blood pressure. Endothelial dysfunction was defined as FMD of less than 1.6%.
Multivariate Analysis of Vascular Smooth Muscle Dysfunction in No Coffee and Coffee Groups.
| Odds ratio (95% Confidence Interval); | |||||
|---|---|---|---|---|---|
| Coffee | Unadjusted | Model 1 | Model 2 | Model 3 | Model 4 |
| No coffee | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) | 1 (reference) |
| Coffee | 0.51 (0.30–0.86); 0.01 | 0.49 (0.28–0.84); 0.01 | 0.45 (0.25–0.78); <0.01 | 0.49 (0.27–0.87); 0.02 | 0.50 (0.28–0.89); 0.02 |
Model 1: adjusted for age, sex, and body mass index. Model 2: adjusted for age, sex, body mass index, dyslipidemia, diabetes mellitus, and smokers. Model 3: adjusted for age, sex, body mass index, dyslipidemia, diabetes mellitus, smoker, cardiovascular disease. Model 4; adjusted for age, sex, body mass index, dyslipidemia, diabetes mellitus, smokers, cardiovascular disease, and systolic blood pressure. Vascular smooth muscle dysfunction was defined as NID of less than 8.4%.
Figure 2Cubic splines of the relationships of amount of daily coffee intake with log odds ratios for endothelial dysfunction (A) and vascular smooth muscle function (B). Endothelial dysfunction was defined as flow-mediated vasodilation of less than 1.6% and vascular smooth muscle dysfunction was defined as nitroglycerine-induced vasodilation of less than 8.4%. Vertical lines show 95% confidence intervals.